FGFR2 and intrahepatic cholangiocarcinoma: The National Comprehensive Cancer Network (NCCN) recommends second-line treatment with FGFR kinase inhibitors for ICC patients with FGFR2 fusions/rearrangements and modified FOLFOX (mFOLFOX: a combination of oxaliplatin, folinic acid, and fluorouracil) for those without FGFR2 alterations [8].